Innovent and Lilly Cancer Drug Approved in China
October 09 2020 - 8:51AM
Dow Jones News
By Michael Dabaie
Innovent Biologics Inc. and Eli Lilly and Co. said Halpryza was
approved by the National Medical Products Administration of China
for patients with diffuse large b cell lymphoma, follicular
lymphoma, and chronic lymphocytic leukemia in China.
Halpryza is an antibody drug co-developed by Innovent and
Lilly.
"Lymphoma is one of the malignant tumors with rapid growing
incidence. However, the survival rate is also relatively higher
than other tumor types when having appropriate treatment," said Li
Wang, senior vice president of Lilly China and head of Lilly China
Drug Development and Medical Affairs Center.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
October 09, 2020 08:36 ET (12:36 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024
